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Abstract
 
B7H/B7RP (hereby called B7H) is a new member of the B7 family of costimulatory molecules
and interacts with inducible costimulatory molecule (ICOS). Its function for CD8 T cells has
not been reported. We report here that expression of B7H on the tumor cells reduced tumori-
genicity and induced immunity to subsequent challenge with parental tumor cells. The im-
mune protection correlates with an enhanced cytotoxic T lymphocyte (CTL) response against
P1A, the major tumor antigen expressed in the J558 tumor. To understand the mechanism of
immune protection, we adoptively transferred transgenic T cells specific for tumor antigen P1A
into mice that bore P1A-expressing tumors. We found that while the transgenic T cells divided
faster in mice bearing the B7H
 
 
 
 tumors, optimal B7H-induced clonal expansion of P1CTL re-
quired costimulation by B7–1 and B7–2 on the endogenous host antigen-presenting cells
(APCs). Interestingly, when B7H
 
 
 
 and B7H
 
 
 
 tumors were coinjected, P1CTL selectively
eliminated the B7H
 
 
 
 tumor cells. Moreover, B7H expressed on the tumor cells made them
highly susceptible to destruction by CTL in vivo, even if the CTL was administrated into mice
with large tumor burdens. Tumors that recurred in the P1CTL-treated mice lost transfected
B7H and/or H-2L
 
d
 
, the class I molecule that presents the P1A peptide. Taken together, our re-
sults reveal that B7H costimulates clonal expansion of, and cognate destruction by CD8
 
 
 
 T
lymphocytes in vivo.
Key words: cytotoxic T lymphocytes • tumor immunity • B7H • effector function • clonal 
expansion
 
Introduction
 
An important feature of the immune response is the multi-
tude of regulation. An important issue is whether an im-
mune response is regulated at both the inductive and effec-
tor phases. While multiple factors, such as antigen (1),
costimulation (2–5), CD4 T cell help (6), and APCs (7)
regulate the induction of CTL responses, the mechanisms
responsible for regulating the effector function of T cells
have not been fully elucidated.
Perhaps the most striking demonstration of controls at
the effector phase is that tumor-reactive CTLs coexist with
the cancer cells in vivo. Thus, we have demonstrated that
P1A-expressing plasmocytoma J558 grew in the transgenic
mice that express a P1A-specific TCR in an overwhelming
number of T cells (8). Moreover, despite a lack of overt im-
mune suppression on antigen-specific CTLs, established
cancers are highly resistant to transgenic tumor-specific
CTLs (9). Corresponding to the observations in experi-
mental animals, several groups reported that melanomas
progressed in many patients despite the high number of
CTL-specific for melanoma (10, 11). While some have ob-
served clear functional defects among these tumor-reactive
T cells (10), others have failed to do so (11). These observa-
tions raise an intriguing possibility that the effector function
of tumor-reactive T cells is normally restrained in vivo.
We (8, 12) and others (13, 14) have reported that ex-
pression of costimulatory molecule B7–1 on tumors pro-
moted T cell effector function. For instance, when B7–1
 
 
 
and B7–1
 
 
 
 tumors were injected into the same mouse, tu-
mor-specific T cells preferentially eliminated B7–1
 
 
 
 tu-
mors (8, 12). Corresponding to this, we reported that
downregulation of either transfected B7–1 or MHC class I
molecules is sufficient to allow tumor recurrence in the
mice that had originally rejected the tumor (15). Thus, the
costimulatory molecule B7–1 played a significant role in
the destruction of tumor cells by CTLs in vivo. Similarly,
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in the autoimmune nonobese diabetic (NOD) model,
when B7–1 was expressed in some, but not all pancreatic
islet cells, the T cells preferentially destroyed the B7–1
 
 
 
 
 
-cells (16). The selective destruction of the B7–1
 
 
 
 cells
over the surrounding B7–1
 
 
 
 cells suggests that costimula-
tory molecule B7–1 can promote the effector function of
autoreactive CTLs.
A fundamental issue raised by these studies is whether
the CTL effector function is controlled by the costimula-
tory molecules, much as is the induction. A major obstacle
to this notion is that B7–1 is neither present nor considered
inducible on the nonhematopoietic tissues which CD8 T
cells can efficiently survey. In this regard, the recently un-
covered members of the B7 family, B7H1 (17) or PDL1
(18) and B7H (19) (20), B7H3 (21), and PD-L2 (22) or
B7-DC (22) have considerably wider tissue distribution.
Northern blot analysis of RNA expression suggested that
B7H is expressed in the heart, lung, and kidney at levels
comparable to those in the spleen and thymus; and that B7-
H1 mRNA is abundant in heart, skeletal muscle, placenta,
and lung tissues, but is weak in thymus, spleen, kidney, and
liver tissues (17, 23). Moreover, B7H is inducible by proin-
flammatory cytokines such as interferon and tumor necrosis
factor (19, 24, 25), and its receptor inducible costimulatory
molecule (ICOS)
 
*
 
 is expressed on activated, but not rest-
ing, T cells (26). It is thus plausible that B7H may act as a
costimulator late in the immune response when T cells
have reached target tissues. To address this important issue,
we expressed B7H on a P1A-expressing tumor cell line
J558, and used P1A-specific transgenic T cells to analyze
the role for B7H in antitumor CTL response in vivo. Here
we report that, in addition to promoting CD8 T cell clonal
expansion, B7H expressed on the tumor cells drastically
enhanced cognate destruction of cancer cells by CD8 T
cells in vivo. Our study provides direct evidence that B7H
costimulates CD8 T cells in vivo. Moreover, our data sup-
port the notion that costimulation is an important parame-
ter in the effector function of T cells.
 
Materials and Methods
 
Experimental Animals.
 
Transgenic mice expressing TCR spe-
cific for tumor antigen P1A35–43:L
 
d
 
 complex have been de-
scribed (8). The TCR transgenes were backcrossed with BALB/
cByJ for at least eight generations before they were used for this
study. Wild-type BALB/c mice were purchased from National
Cancer Institute. BALB/c mice with a targeted mutation of
RAG-2 gene were purchased from Taconic.
 
Construction of B7H-Green Fluorescent Protein Fusion Gene and
Production of B7H-transfected J558 Cells.
 
Total RNA was isolated
from the mouse spleen cells by TRIzol (GIBCO BRL) and 2 
 
 
 
g
of total RNA were used for first strand cDNA synthesis using the
random hexamers (GIBCO BRL). The mouse B7H cDNA was
amplified by PCR using Pfu DNA polymerase (forward primer:
ATGCAGCTAAAGTGTCCCTGT and reverse primer: GGC-
GTGGTCTGTAAGTTCAAG). The PCR amplified B7H frag-
ment was cloned into the BamHI and EcoRI sites of pEGFP-N3
(CLONTECH Laboratories, Inc.). The positive clones were se-
quenced using a primer in the pCMV IE region. The mB7H–
green fluorescent protein (GFP) fusion DNA was transfected into
the J558 cell line using DMRIE reagent (Life Technologies) and
the presence of B7H and GFP was verified by reverse transcrip-
tion (RT)-PCR and flow cytometry.
 
Cell Lines.
 
Plasmocytomas J558 transfected with either vec-
tor alone (J558-Neo), or B7–1 (J558-B7–1) have been described
(12). Three independent clones of J558-B7H were produced as
described above and used for the current study.
 
Antibodies and Fusion Protein.
 
Anti–B7–1 (3A12) (27) and
anti–B7–2 (GL-1) mAbs (28) were purified from the hybridoma
supernatants using protein G affinity column. For in vitro analy-
sis, the antibodies were biotinylated. Cy-chrome-conjugated
anti-CD8, PE-conjugated anti-V
 
 
 
8, and biotinylated anti–H2-L
 
d
 
mAb HB27 were purchased from BD PharMingen.
The extracellular portion of murine ICOS was amplified by
RT-PCR using cDNA from mouse spleen as template, 5
 
 
 
-AT-
GAAGCCGTACTTCTGCCATG as forward primer, 5
 
 
 
-TCT-
TCAGCTGGCAGCAGAGCTGGG as the reverse primer. The
PCR product was cloned into the pIg vector (Novagen). ICOSIg
fusion gene was then inserted into HindIII/KpnI site of
pcDNA3.1/Hygro
 
 
 
 (Invitrogen). The construct was transfected
into CHO cells using Fugene 6 transfection system (Boehringer).
The Hygromycin B resistant clones were expanded. The ICOSIg
protein was purified using protein G column.
 
Adoptive Transfer of Purified Transgenic T Cells.
 
Pools of spleen
and lymph node cells from the recombination activating gene
(RAG)-2
 
 
 
/
 
 
 
 
 
or RAG-2
 
 
 
/
 
 
 
 P1CTL-transgenic mice were incu-
bated with a cocktail of mAbs (anti-CD4 mAb GK1.5, anti-FcR
mAb 2.4G2, anti-CD11c mAb N418). After removal of un-
bound mAbs, the cells were incubated with anti-Ig–coated mag-
netic beads. The antibody-coated cells were removed by a mag-
net. The unbound cells consisted of more than 90% CD8 T cells,
with no detectable CD4 T cells. The purified T cells were adop-
tively transferred into RAG-2
 
 
 
/
 
 
 
 
 
mice that either had established
tumors, or had received tumor cells on the same day of adoptive
transfer. In some experiments, the CD8 T cells were labeled with
CFSE before their adoptive transfer as described (29).
 
Tumorigenicity Assay.
 
5 
 
 
 
 10
 
6
 
 J558 cells were injected in the
flanks as described (12). The tumor size and incidence were de-
termined by physical examination.
 
CTL Assays.
 
A 6-h 
 
51
 
Cr release assay was used to measure
CTL activity. The effector T cells were either the P1CTL acti-
vated for 96 h with 0.1 
 
 
 
g/ml of P1A peptide (8), or tumor-
infiltrating lymphocytes isolated from either J558-B7H or J558-
Neo tumors, as described (12).
 
Results
 
B7H-expressing Tumors Induce Stronger Antitumor CTL
Response in Wild-Type Mice.
 
As no anti-B7H mAb is avail-
able at this point, we have produced a fusion gene encod-
ing a B7H-GFP chimera protein which can be easily
quantitated by flow cytometry. The plasmid containing
B7H-GFP was therefore used to transfect the J558 cells.
After selection with G418, the drug resistant clones were
screened by flow cytometry. Three independent clones
were selected for the current studies. As shown in Fig. 1 A,
all three clones expressed significant levels of B7H-GFP. Fu-
 
*
 
Abbreviations used in this paper:
 
 GFP, green fluorescence protein; ICOS,
inducible costimulatory molecule; RAG, recombination activating genes;
TIL, tumor-infiltrating lymphocyte. 
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sion with GFP did not abrogate the function of B7H as the
J558-B7H-GFP can bind to ICOSIg (Fig. 1 B). Moreover,
the B7H-GFP is expressed on the cell surface as revealed
by confocal microscopy (data not shown). To avoid varia-
tion of individual clones, we maintained the clones indi-
vidually, but mixed equal numbers of cells from the three
clones for all the experiments described in the current
study. As shown in Fig. 1 C, both J558-Neo and J558-
B7H expressed and presented the tumor antigen P1A as
they were readily killed by P1A-specific transgenic T cells.
While B7–1 significantly increased lysis of J558 cells by
CTL as we have described (12), B7H did not substantially
enhance the lysis by P1CTL in vitro.
Expression of GFP as a cytosolic protein drastically re-
duced the growth rate of the J558 cells in vitro and the tu-
morigencity of J558 even in RAG-2
 
 
 
/
 
 
 
 
 
mice that do not
have T and B lymphocytes (data not shown). This is not
the case for B7H-GFP, which was expressed on the cell
surface and did not affect cell growth rate and tumorige-
nicity in the absence of T and B lymphocytes (Fig. 2 B; see
also Figs. 7 B and 8 C). We therefore used J558 cells trans-
fected with vector alone as control for this study. We
tested the tumorigenicity of the J558-B7H and J558-Neo
in syngeneic BALB/c mice. As shown in Fig. 2, all mice
that received the J558-Neo tumor cells developed palpable
tumors within 11 d, while only 10% of the mice inocu-
lated with the J558-B7H cells developed tumors during
the same period. Although 60% of the mice did develop
tumors within a 6-wk period, the remaining 40% of the
mice never developed tumors. In contrast, in the immune
deficient RAG-2
 
 
 
/
 
 
 
 
 
mice, the two tumor cell lines in-
duced tumors at a similar rate. Thus, while nonspecific im-
munity may cause a minor reduction of the tumorigenicity
of the B7H-transfected J558 cells, the decreased tumorige-
nicity of the B7H-transfected tumor cells is primarily due
to specific immune response. To confirm that the immu-
nity was not solely specific for any part of the B7H-GFP
fusion protein, we challenged the mice that had rejected
the J558-B7H tumor with the parental J558 cells. As
shown in Fig. 2, C and D, while 100% of the naive mice
developed the J558 tumors at the site of injection, none of
the mice that rejected the J558-B7H tumors develop the
J558 tumors.
A major tumor antigen in the J558 tumor is P1A (30).
To verify that expression of B7H on the tumor cells en-
hances antitumor immune response, we evaluated anti-P1A
CTL response in tumor-infiltrating lymphocytes (TILs)
from the J558-Neo and J558-B7H tumors. As shown in
Fig. 3 A, J558-B7H was infiltrated a large number of
CD8
 
 
 
 T cells, and essentially all CD8
 
 
 
 T cells expressed
high levels of CD44. While J558-Neo was also infiltrated
with activated CD8 T cells, its frequency was 
 
 
 
20-fold
lower. Moreover, strong P1A-specific CTL activity was
observed in the TIL of the J558-B7H tumors, but not in
those of the J558-Neo tumors (Fig. 3 B). TIL from J558-
B7H kills both J558-B7H and J558-Neo targets (Fig. 3 C).
Thus, B7H enhanced antitumor CTL response, including
the anti-P1A CTL response in vivo.
 
B7H Costimulates Clonal Expansion of Tumor-specific T
Cells, Although Optimal In Vivo Division of P1CTL Depends
on B7–1/2 on Host APCs.
 
We have recently produced a
transgenic mouse line that expresses TCR-specific for P1A,
which we called P1CTL (8). To analyze if the B7H pro-
motes the induction of T cell clonal expansion, we labeled
the purified transgenic CD8 T cells with CFSE and stimu-
lated them with either J558-Neo or J558-B7H cells. As
Figure 1. Generation of tumor cell lines expressing B7H-GFP fusion protein. (A) Intensity of green fluorescence in J558 cells transfected with vector
alone (J558-Neo) or B7H-GFP. Profiles of three independent clones were presented. These clones were cultured separately, mixed at an 1:1:1 ratio, and
used in all subsequent experiments. (B) ICOSIg binds to J558-B7H, but not to J558-Neo. The J558-transfectants were incubated with either human
IgG1Fc or ICOSIg (50  g/ml), and the binding was measured by flow cytometry. (C) Susceptibility of J558-B7H, J558-Neo, and J558-B7 to transgenic
P1CTL, which had been stimulated in vitro for 4 d with P1A peptide (0.1  g/ml). Two independent experiments were presented. Unpulsed or P1A-
pulsed P388D1(H-2d) target cells were used as negative and positive controls, respectively. 
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shown in Fig. 4, regardless of the tumor cells used, insignif-
icant T cell division was found at 48 h of coculture. By 72 h,
however, many of the J558-B7H–stimulated T cells had
mounted up to five divisions, while T cells cocultured with
J558-Neo barely divided. Both groups divided at 96 h after
stimulation (data not shown), although there were approxi-
mately fivefold more nondividing P1CTL in the J558-Neo
stimulated culture (
 
 
 
10%) than the J558-B7H–stimulated
Figure 2. B7H expression reduced tumorigenicity of
the J558 cells in immune competent mice and induced
protection to subsequent challenge with the parental tu-
mors. (A) Tumor incidence of J558-Neo (n     6) and
J558-B7H (n   10) in immune competent mice. Data are
representative of four independent experiments. In total,
24/26 mice receiving J558-Neo cells developed tumors,
while 23/39 mice receiving the J558-B7H cells developed
tumors. (B) J558-B7H and J558-Neo tumors grew at a
similar rate in syngeneic RAG-2 /  mice (n   7). Data
shown are representative of four independent experiments,
which in total involved 23 mice per group. All mice de-
veloped tumors within 2 wk. Syngeneic BALB/c or
BALB/crag2 /  mice received 5   106 tumor cells in the
flank, and the tumor incidences were determined by phys-
ical examination. (C and D) Mice that rejected J558-B7H
tumors were immune to subsequent challenge with paren-
tal J558 cells. Syngeneic BALB/c mice that had rejected
J558-B7H tumors and naive control mice were challenged
with 5   106 J558 cells at the opposite flank. The tumor
incidence (C) and growth kinetics (D) were measured by
physical examination. This experiment was repeated twice
with similar results.
Figure 3. B7H increases P1A-specific CTL in the TIL from wild-
type BALB/c mice. The TIL were enriched by depletion tumor cells as
described (reference 12). The cytotoxicity of the freshly isolated TIL
were determined using either P1A-pulsed or unpulsed P388D1, or the
J558-Neo and J558-B7H cells as targets. (A) Substantial increase of acti-
vated CD8 T cells among the TIL. The TIL were stained with PE-con-
jugated anti-CD8 and Cy-conjugated anti-CD44 mAbs and analyzed
by flow cytometry. (B) P1A-specific CTL in the TIL from the J558-B7H, but not the J558-Neo tumors. Freshly isolated TIL were used as effectors
while the P1A-pulsed and unpulsed P388D1 were used as targets. (C) TIL from J558-B7H (right panel), but not those from J558-Neo (left panel), lysed
both J558-B7H and J558-Neo tumors. As in B, except that the J558-Neo and J558-B7H were also used as targets. Data shown are representative of at
least three independent experiments. TIL used in A and B were isolated at day 24 of tumor injection, while those used in C were isolated on day 20 of
tumor cell injection. 
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culture (
 
 
 
2%). Thus, B7H accelerated T cell clonal expan-
sion in vitro.
To test the function of B7H for CD8 T cell activation in
vivo, we labeled P1CTL with CFSE and adoptively trans-
ferred them into syngeneic RAG-2
 
 
 
/
 
 
 
 
 
mice that were ei-
ther tumor-free or bore either J558-Neo or J558-B7H tu-
mors. At 36, 60, and 84 h after the T cell transfer, spleen
cells were harvested, and the number of divisions that the
transgenic T cells had undergone in vivo was analyzed by
flow cytometry. As shown in Fig. 5, left panels, P1CTL di-
vided slowly in the tumor-free mice, with a significant
number of T cell dividing only at 84 h of adoptive transfer.
In the mice that bore the J558-Neo tumors, few cells di-
vided at 36 h of transfer. By 60 h, most of the cells in the
spleen were products of one to six divisions, and an over-
whelming majority of the cells accumulated at 84 h were
products of six or more divisions. Interestingly, the P1CTL
had divided significantly faster in the mice that bore the
J558-B7H tumors. Thus, significant divisions of T cells
were already detected at 36 h of transfer in the J558-B7H
tumor-bearing mice. By 60 h, an overwhelming majority
of the T cells accumulated in the spleen had divided more
than four times. Corresponding to this, substantially more
T cells had accumulated in the spleen of J558-B7H tumor
bearing mice at 60 and 84 h after adoptive transfer (Fig. 5).
To test if costimulation by B7–1 and B7–2 on the host
APCs is required for clonal expansion of T cells, we in-
jected anti–B7–1 and anti–B7–2 mAbs in mice that bore
J558-B7H tumors and analyzed the division of T cells in
the spleens. As the J558 tumor cells did not express B7–1
and B7–2, even during an ongoing immune response in
vivo (31), the anti-B7 mAbs must have blocked the costim-
ulatory function of B7–1 and B7–2 on the host APCs. As
shown in Fig. 6, anti–B7–1 and anti–B7–2 substantially
reduced the division rate of T cells. Thus, despite B7H ex-
pression on the tumor cells, optimal activation of tumor-
specific T cells requires costimulation by B7–1 and/or
B7–2 expressed on the host APCs.
 
B7H Promotes the Cognate Destruction of Cancer Cells In
Vivo.
 
To test if B7H may play a role subsequent to the
initial T cell activation, such as the effector function of T
Figure 4. B7H expressed on the tumor cells promotes clonal expan-
sion of purified P1CTL. Purified CD8 T cells from P1CTL transgenic
mice were labeled with CFSE and stimulated with irradiated J558-Neo
or J558-B7H for either 48 or 72 h. The viable cells were stained with
PE-anti-V 8 and Cy-anti-CD8 mAbs. The data shown are histograms
of gated CD8 V 8  T cells. This experiment was repeated twice with
similar results.
Figure 5. Expression of B7H on the tumor cells pro-
motes T cell clonal expansion. Purified CD8 T cells from
P1CTL transgenic mice were labeled with CFSE and
adoptively transferred into RAG-2 /  BALB/c mice bear-
ing either J558-Neo or J558-B7H tumors, or mice that re-
ceived no tumor cells as control. At 36, 60, and 84 h after
the adoptive transfer, T cells were isolated from either
spleen or tumors and were analyzed for the number of di-
visions that they had undergone. FACS® profiles of CFSE
intensity of gated CD8 V 8  T cells isolated from spleen
were presented. The percent of the CD8 Va8  cells were
shown in the panels. 
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cells, we injected a mixture of J558-B7H and J558-Neo
into syngeneic RAG-2
 
 
 
/
 
 
 
 
 
mice in the presence or absence
of tumor-specific T cells. Despite of the fact that P1CTL
successfully delayed the growth of tumors, the majority of
the mice eventually developed tumors at the site of injec-
tion (Fig. 7 A). To determine the origin of the tumor cells,
we isolated the tumor cells and analyzed the expression of
B7H by flow cytometry. As shown in Fig. 7 B, top panel,
tumor cells recovered from mice that received no T cells
consisted of a mixture of both B7H
 
 
 
 and B7H
 
 
 
 subpopu-
lations. The nearly equal contribution of the two types of
tumor cells indicated that B7H expression did not convey a
significant growth disadvantage in the absence of P1CTL.
In contrast, in mice that received P1CTL, all tumor cells
that survived in vivo were devoid of B7H. As the B7H
 
 
 
and B7H
 
 
 
 cells were injected as a mixture, selective elimi-
nation of B7H
 
 
 
 tumor cells indicates that B7H promotes
the cognate destruction of tumor cells.
A major caveat of the above experiment is that T cells
that mediate the rejection can be specific for the GFP fu-
sion protein, as the T cells used in the above experiments
were from transgenic mice that may have had rearrange-
ment of the endogenous TCR. To rule out this possibility,
we bred the P1CTL into the syngeneic RAG-2
 
 
 
/
 
 
 
 
 
back-
ground to produce the RAG-2
 
 
 
/
 
 
 
 P1CTL. As shown in
Fig. 8, RAG-2
 
 
 
/
 
  
 
P1CTL was at least as efficient as the
RAG
 
 
 
/
 
  
 
P1CTL (Fig. 7) in rejecting a mixture of the
J558-B7H and J558-Neo tumors. In addition, the RAG-
2
 
 
 
/
 
  
 
P1CTL divided faster in mice that bore the J558-B7H
tumor (Fig. 8 B), much as the RAG-
 
 
 
/
 
  
 
P1CTL (Fig. 5).
Moreover, the tumor cells that survived the RAG-2
 
 
 
/
 
 
 
P1CTL were predominantly B7H
 
 
 
 (Fig. 8 C). These re-
sults confirmed that the function of B7H described here
was not due to the antigenicity of the GFP.
 
Established B7H-expressing Tumor Cells Are Highly Sensi-
tive to T Cell Therapy.
 
A major challenge in tumor immu-
notherapy is to eliminate the established tumors. As B7H
promoted cognate destruction of J558 tumors, we tested if
expression of B7H allowed T cells to eliminate large bur-
dens of tumors. We injected RAG-2
 
 
 
/
 
 
 
 
 
mice with either
J558-Neo or J558-B7H tumor cells. At 3 wk after tumor
inoculation when the tumors had reached a diameter 
 
 
 
1.5
cm, we adoptively transferred 5 
 
 
 
 10
 
6 P1CTL. As shown
in Fig. 9 A, P1CTL caused a temporary reduction in the
size of the J558-Neo tumors. However, after a short pause,
the J558-Neo tumor progressed rapidly and all mice suc-
cumbed to the tumor shortly thereafter. Interestingly, in
the two mice with the J558-B7H tumor and P1CTL, the
tumor rapidly shrank to either impalpable (J558-B7H-A),
or into a small debris of  2 mm with no tumor when ex-
amined by biopsies (J558-B7H-B). These results suggest
that expression of B7H enhanced tumor susceptibility to T
cell therapy.
Eventually, the tumors originated from the B7H  cells
recurred and grew progressively. As mice with recurrent
tumors had large numbers of P1CTL (data not shown), we
isolated the tumor cells and analyzed the cell surface ex-
pression of H-2Ld, the restricting element for the P1A pep-
tide, and B7H. As shown in Fig. 9 B, in comparison to the
parental J558-B7H tumor cells, almost all cells from the
J558-B7H-A had reduced cell surface H-2Ld by 10-fold
and the majority of the tumor cells also downregulated the
B7H. This is consistent with our previous reports (15, 32).
Interestingly, the cells from J558-B7H-B maintained a sub-
stantial level of H-2Ld, but lost all B7H. Selective loss of
B7H in the recurrent tumors reaffirms the notion that B7H
promotes CTL recognition of tumor cells in vivo.
Discussion
An important advance in the area of T cell costimulation
is the identification of the members of the extended B7
family and their receptors (17, 19–21, 26, 33). Until now,
most studies have focused on the roles of new B7 family
members in CD4 T cells responses. Although the function
Figure 6. B7–1 and/or B7–2 on host cells were required for optimal T
cell division in vivo. (A) The amount of V 8  T cells recovered from the
spleen, the percentages of the P1CTL recovered were given in the panel.
(B) Distributions of CFSE intensities among the V 8  T cells. Naive
P1CTL were labeled with CFSE and adoptively transferred into the
RAG-2 /  J558-B7H tumor-bearing mice that had received either con-
trol (a mixture of rat and hamster) IgG or anti–B7–1 and B7–2 mAbs on
days 0, 1, and 2 of T cell adoptive transfer. Spleen cells were harvested
and analyzed on day 3 of the adoptive transfer. This experiment was re-
peated twice with similar results.1345 Liu et al.
Figure 7. Selective elimination of B7H-
expressing tumor cells by transgenic T cells
in vivo. J558-Neo and J558-B7H were
mixed at 1:1 ratio and injected into the flank
of the BALB/c RAG-2 /  mice. Half of
the mice received 5   106 of P1CTL intra-
peritoneally at the same day. (A) P1CTL de-
layed the development of tumor cells. Data
presented were percentage of mice with pal-
pable tumors at different times after injec-
tion of tumor cells. (B) Selective elimination
of B7H cells by P1CTL. Top, substantially
comparable representation of J558-B7H and
J558-Neo tumor cells. Mice were killed
when the tumor reached  5% body weight
(3 wk after injection), and the freshly iso-
lated tumor cells were analyzed for both
GFP intensity and for tumor markers, the
plasma cell antigen PC1 that is present on
tumor cells, but not on host cells in the
RAG-2 /  host. Data presented are the his-
tograms of gated PC1  tumor cells. Note
that about half of the tumor cells expressed
B7H. Bottom, tumor cells isolated by biop-
sies were all devoid of GFP. At 7 wk after
injection, the tumor cells were isolated by
needle biopsies from at least three locations
in the tumors. After a short-term culture
( 1 wk), their GFP intensity was analyzed
by flow cytometry. Note that all ex vivo tu-
mor cells (plain lines) were devoid of B7H.
A J558-B7H cell line was used as control.
Figure 8. RAG-2 /  P1CTL proliferate more rapidly in mice bearing
J558-B7H tumors than in the J588-Neo tumor-bearing mice, and prefer-
entially reject B7H  tumors. (A) Tumor rejection. RAG-2 /  BALB/c
mice were inoculated with a mixture (1:1) of J558-Neo and J558-B7H
cells. One group of mice also received 5   106 RAG-2 /  P1CTL. Tu-
mor incidence was determined by physical examination. (B) T cell divi-
sion in vivo. RAG-2 /  P1CTL were labeled with CFSE and adoptively
transferred into mice that bore J558-B7H (dotted line) or J558-Neo (bold
line) tumors of comparable sizes. Spleen cells were harvested at 60 h after
adoptive transfer, and stained with PE-anti-V 8 and Cy-anti-CD8 mAbs.
Data shown are the histograms of CFSE intensity of the gated
CD8 V 8  T cells (14.8% of spleen cells in the J558-B7H group and
2.2% in the J558-Neo group). (C) Preferential rejection of the B7H  tu-
mors. Tumors cells were isolated from mice that received 1:1 ratio of
J558-B7H and J558-Neo cells with or without RAG-2 /  P1CTL. The
presence of B7H  tumor cells was measured based on the GFP  cells.
Top panels depict two representative tumors from mice that did not re-
ceive T cells, while the two bottom panels depict those that received T
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of other members is still controversial (17, 18, 21, 22, 33,
34), accumulating evidence supports a critical role for
B7H–ICOS interaction in the induction and the effector
function of Th2 cells, including the induction of germinal
center formation, regulation of Th1 response, and develop-
ment of allergy and autoimmune disease (33, 35, 36). Es-
sentially all of these studies have focused on CD4 T cells,
and the function of the new B7 family members for CD8 T
cells has not been reported.
The results presented in this study showed that B7H pro-
moted both clonal expansion and effector function of tu-
mor-specific CD8 T cells in vivo. Thus, in syngeneic mice,
transfection with the B7H-GFP gene induced rejection of
J558-B7H-GFP and subsequent immunity to unmodified
J558 cells. Corresponding to this, we observed that the TIL
isolated from J558-B7H, but not J558-Neo, had strong ex
vivo cytotoxicity specific for P1A, the major tumor antigen
expressed on the J558 tumors. As adoptive transfer of
RAG-2 /  P1CTL conferred protection in the absence of
other antigen-specific T cells, it is most likely that the en-
hanced P1A-specific CTL response contributed to the re-
jection of J558 tumors in the syngeneic nontransgenic mice.
B7H-expressing J558 tumor cells are substantially more
potent in inducing clonal expansion of tumor-specific T
cells. Interestingly, clonal expansion of P1CTL in vivo re-
quires costimulation by B7–1 and B7–2. As B7–1 and B7–2
are neither expressed, nor induced on the J558 tumor cells
(31), it is likely that anti–B7–1/2 blocked cross-presenta-
tion of P1A antigen by host APCs. Consistent with this, we
have recently demonstrated that both direct and cross-pre-
sentation of P1A antigen to T cells leads to activation of
P1A-specific CTL in vivo (37). The fact B7H enhance
clonal expansion of tumor-specific T cells in vivo explains
the increased number of tumor-specific CTLs among the
B7H TIL, and the increased immunity to subsequent chal-
lenge with parental tumor cells. However, when P1CTL
were adoptively transferred to mice that had a mixture of
both B7H  and B7H  cells, the T cells preferentially re-
jected the B7H  tumor cells. More strikingly, the increased
susceptibility of the B7H  tumors could be observed even
when the tumors were allowed to grow to 1–2 cm in di-
ameter before T cell transfer. The mechanism by which
B7H promotes cognate destruction of J558-tumor in vivo
is not fully understood at the present. As the effect of B7H
on tumor cell susceptibility is modest at best, the simplest
interpretation, that B7H promote cytolysis of tumor cells to
CTL lysis, while not excluded, may not explain the en-
hanced cognate destruction. Moreover, we have not ob-
served induction of cytokine gene expression by B7H, as
measured by RNase protection (data not shown).
We and others have observed that expression of B7–1
on the tumor cells promotes destruction of tumor cells in
vivo. While Wu et al. (13) suggested that enhanced lysis by
NK cells is responsible, our results demonstrated that B7–1
enhanced CTL-mediated rejection of J558 cells in vivo,
and enhanced cytolysis in vitro (12). It is worth mention-
Figure 9. B7H expression increased sus-
ceptibility of established tumors to T cell
therapy. J558-Neo and J558-B7H tumors
were allowed to grow in the BALB/crag-2 / 
mice for three weeks until they reached
 1.5 cm in diameter. Transgenic T cells
(5   106/mouse) were then injected intra-
peritoneally. (A) Tumor size after T cell in-
jection. Note the complete disappearance
and recurrence of the J558-B7H tumors. *,
found dead; ** moribund and killed. (B).
Mechanism of tumor recurrence. Analysis
of cell surface expression of MHC class I
H-2Ld, and B7H. Left, a J558-B7H cell line
as control. Middle, phenotype of the J558-
B7H-A tumor cells. Right, phenotype of
the J558-B7H-B tumor cells.1347 Liu et al.
ing that for at least three lineages of P1A-expressing tu-
mors, J558, Meth A, and P815, B7–1 expressed on the tu-
mor cells promoted cognate destruction of tumor cells
(38). As expression of B7–1 did not enhance lysis of P815
and Meth A by P1CTL (data not shown), it is unlikely that
enhanced lysis as measured by the in vitro CTL was essen-
tial for the function of B7–1 at the effector phase. Regard-
less of the mechanism, the role for B7–1 at the effector
phase indicated that the effector function of antitumor
CTL can be regulated in vivo. Even though B7H is not
unique in its intrinsic ability to promote the cognate de-
struction of tumor cells, the expression pattern of B7H and
its receptor ICOS suggests an important implication of our
results. Unlike B7–1 and B7–2, which appear restricted to
the hematopoietic cells in vivo, the B7H gene is expressed
in essentially all nonhematopoietic tissues tested, such as
the heart, lung, brain, kidney, and liver (23). In addition,
B7H is highly inducible by proinflammatory cytokines
such as tumor necrosis factor and interferon   (19, 24, 25).
As activated, but not resting, T cells express ICOS (26), it
is possible that the effector function of activated T cells is
regulated by B7H, and that inflammation may ultimately
determine target susceptibility to CTL recognition. Fi-
nally, as B7H enhances tumor susceptibility to T cell ther-
apy, one may be able to tap into the potential of the large
number of tumor-specific T cells in the melanoma patients
(10, 11) by activating B7H-mediated signal transduction
within the tumor milieu.
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